Silo Pharma Inc. SILO has agreed University of Columbia on an expansion of the psychedelics biotech’s option to license certain treatments for now in development, incl Alzheimer’s disease and stress-related anxiety.

The compounds evaluated in Columbia’s study, whose first steps have shown positive results, are two of them Silos proprietary pipeline: SPC-14a novel drug combining two approved therapeutics targeting NDMARS and 5HT4Rs to treat cognitive and neuropsychiatric symptoms in Alzheimer’s and SPC-15which uses ketamine compositions as a method of treating and preventing stress-induced mood disorders.

The contract extension includes the work of dr Christine Ann DennyAssociate Professor of Clinical Neurobiology in Psychiatry Irving Medical Center at Columbia University.

dr Denny and her team focus on evaluating the Molecular Mechanisms behind learning and memory, including diseases like Alzheimer’s, and whether ketamine and other novel drugs can improve memory retrieval, halt or even reverse the process of memory loss or cognitive aging.

Positive results could keep from this study life changing effects for people suffering from pathologies ranging from Alzheimer’s disease to PTSD.

Meanwhile, Silo is conducting parallel research studies including the joint venture with Zylo Therapeutics for the development of a time-release dermal delivery system of ketamine or psilocybin for multiple health indications; and a research agreement with the University of California to study the effect of psilocybin on blood inflammation targeting Parkinson’s disease, chronic pain and bipolar disorder.

Photo courtesy of Commons and Pexels.